These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

701 related items for PubMed ID: 11493400

  • 1. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
    Mentzer SJ, Perrine SP, Faller DV.
    Transpl Infect Dis; 2001 Sep; 3(3):177-85. PubMed ID: 11493400
    [Abstract] [Full Text] [Related]

  • 2. Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies.
    Faller DV, Mentzer SJ, Perrine SP.
    Curr Opin Oncol; 2001 Sep; 13(5):360-7. PubMed ID: 11555713
    [Abstract] [Full Text] [Related]

  • 3. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma.
    Mentzer SJ, Fingeroth J, Reilly JJ, Perrine SP, Faller DV.
    Blood Cells Mol Dis; 1998 Jun; 24(2):114-23. PubMed ID: 9628848
    [Abstract] [Full Text] [Related]

  • 4. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies.
    Perrine SP, Hermine O, Small T, Suarez F, O'Reilly R, Boulad F, Fingeroth J, Askin M, Levy A, Mentzer SJ, Di Nicola M, Gianni AM, Klein C, Horwitz S, Faller DV.
    Blood; 2007 Mar 15; 109(6):2571-8. PubMed ID: 17119113
    [Abstract] [Full Text] [Related]

  • 5. Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents.
    Ghosh SK, Forman LW, Akinsheye I, Perrine SP, Faller DV.
    Blood Cells Mol Dis; 2007 Mar 15; 38(1):57-65. PubMed ID: 17161633
    [Abstract] [Full Text] [Related]

  • 6. Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target.
    Tse E, Kwong YL.
    Exp Mol Med; 2015 Jan 23; 47(1):e136. PubMed ID: 25613733
    [Abstract] [Full Text] [Related]

  • 7. The biology of Epstein-Barr virus in post-transplant lymphoproliferative disease.
    Hsieh WS, Lemas MV, Ambinder RF.
    Transpl Infect Dis; 1999 Sep 23; 1(3):204-12. PubMed ID: 11428990
    [Abstract] [Full Text] [Related]

  • 8. Epstein-Barr virus latent and replicative gene expression in post-transplant lymphoproliferative disorders and AIDS-related non-Hodgkin's lymphomas. French Study Group of Pathology for HIV-associated Tumors.
    Rea D, Delecluse HJ, Hamilton-Dutoit SJ, Marelle L, Joab I, Edelman L, Finet JF, Raphael M.
    Ann Oncol; 1994 Sep 23; 5 Suppl 1():113-6. PubMed ID: 8172807
    [Abstract] [Full Text] [Related]

  • 9. Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.
    Bilger A, Plowshay J, Ma S, Nawandar D, Barlow EA, Romero-Masters JC, Bristol JA, Li Z, Tsai MH, Delecluse HJ, Kenney SC.
    Oncotarget; 2017 Jul 04; 8(27):44266-44280. PubMed ID: 28574826
    [Abstract] [Full Text] [Related]

  • 10. Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipients.
    Baldanti F, Rognoni V, Cascina A, Oggionni T, Tinelli C, Meloni F.
    Virol J; 2011 Sep 05; 8():421. PubMed ID: 21892950
    [Abstract] [Full Text] [Related]

  • 11. Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatment.
    Petrara MR, Giunco S, Serraino D, Dolcetti R, De Rossi A.
    Cancer Lett; 2015 Dec 01; 369(1):37-44. PubMed ID: 26279520
    [Abstract] [Full Text] [Related]

  • 12. Epstein-Barr virus-associated risk factors for post-transplant lymphoproliferative disease in pediatric liver transplant recipients.
    Quintero Bernabeu J, Juamperez J, Mercadal-Hally M, Larrarte King M, Gallego Melcon S, Gros Subias L, Sábado Álvarez C, Soler-Palacin P, Melendo Pérez S, Esperalba J, Navarro Jiménez A, Garrido Pontnou M, Camacho Soriano J, Hidalgo Llompart E, Bilbao Aguirre I, Charco Torra R.
    Pediatr Transplant; 2022 Sep 01; 26(6):e14292. PubMed ID: 35466492
    [Abstract] [Full Text] [Related]

  • 13. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
    McDiarmid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH, Martín MG, Bahar R, Maxfield AL, Ament ME, Busuttil RW.
    Transplantation; 1998 Dec 27; 66(12):1604-11. PubMed ID: 9884246
    [Abstract] [Full Text] [Related]

  • 14. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
    Davis CL, Harrison KL, McVicar JP, Forg PJ, Bronner MP, Marsh CL.
    Clin Transplant; 1995 Feb 27; 9(1):53-9. PubMed ID: 7742583
    [Abstract] [Full Text] [Related]

  • 15. Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation.
    Rea D, Fourcade C, Leblond V, Rowe M, Joab I, Edelman L, Bitker MO, Gandjbakhch I, Suberbielle C, Farcet JP.
    Transplantation; 1994 Aug 15; 58(3):317-24. PubMed ID: 8053055
    [Abstract] [Full Text] [Related]

  • 16. Posttransplant lymphoproliferative disorder in pediatric renal transplantation.
    Srivastava T, Zwick DL, Rothberg PG, Warady BA.
    Pediatr Nephrol; 1999 Nov 15; 13(9):748-54. PubMed ID: 10603113
    [Abstract] [Full Text] [Related]

  • 17. Epstein-Barr virus encephalitis in solid organ transplantation.
    Lau JSY, Low ZM, Abbott I, Shochet L, Kanellis J, Kitching AR, Korman TM.
    New Microbiol; 2017 Jul 15; 40(3):212-217. PubMed ID: 28513810
    [Abstract] [Full Text] [Related]

  • 18. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A, Prete A, Belotti T, Gibertoni D, Piccirilli G, Gabrielli L, Pession A, Lazzarotto T.
    Transpl Infect Dis; 2016 Feb 15; 18(1):44-54. PubMed ID: 26574232
    [Abstract] [Full Text] [Related]

  • 19. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response.
    Yang J, Tao Q, Flinn IW, Murray PG, Post LE, Ma H, Piantadosi S, Caligiuri MA, Ambinder RF.
    Blood; 2000 Dec 15; 96(13):4055-63. PubMed ID: 11110673
    [Abstract] [Full Text] [Related]

  • 20. Epstein-Barr virus infection and altered control of apoptotic pathways in posttransplant lymphoproliferative disorders.
    Ghigna MR, Reineke T, Rincé P, Schüffler P, El Mchichi B, Fabre M, Jacquemin E, Durrbach A, Samuel D, Joab I, Guettier C, Lucioni M, Paulli M, Tinguely M, Raphael M.
    Pathobiology; 2013 Dec 15; 80(2):53-9. PubMed ID: 22868923
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.